| Identification | |
| Name: | Sitagliptin phosphate monohydrate |
| Synonyms: | 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate monohydrate;Sitagliptin phosphate; |
| CAS: | 654671-77-9 |
| Molecular Formula: | C16H15F6N5O.H3PO4.H2O |
| Molecular Weight: | 523.33 |
| InChI: | InChI=1/C16H15F6N5O.H3O4P.H2O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4;/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4);1H2/t9-;;/m1../s1 |
| Molecular Structure: | ![(C16H15F6N5O.H3PO4.H2O) 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-t...](https://img1.guidechem.com/chem/e/dict/212/654671-77-9.jpg) |
| Properties | |
| Appearance: | White or almost white crystalline powder |
| Specification: |
In clinical trials, adverse effects were as common with sitagliptin (whether used alone or with metformin or pioglitazone) as they were with placebo, except for extremely rare nausea and common cold-like symptoms.There is no significant difference in the occurrence of hypoglycemia between placebo and sitagliptin . |
| Color: | write |
| Safety Data | |
 |
|
